Financial reports
ARS
2023 FY
Annual report to shareholders
25 Apr 24
10-K
2023 FY
Annual report
21 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
10-Q
2023 Q1
Quarterly report
3 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
10-K
2022 FY
Annual report
22 Feb 23
10-Q
2022 Q3
Quarterly report
9 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
Current reports
8-K
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
8 Apr 24
8-K
Entry into a Material Definitive Agreement
29 Feb 24
8-K
Ionis reports fourth quarter and full year 2023 financial results
21 Feb 24
8-K
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
22 Jan 24
8-K
Other Events
21 Dec 23
8-K
Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema
18 Dec 23
8-K
Ionis announces the appointment of Michael Yang to Board of Directors
14 Dec 23
8-K
Ionis reports third quarter 2023 financial results
2 Nov 23
8-K
Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer’s disease and Huntington’s disease
27 Sep 23
8-K
Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome
26 Sep 23
Registration and prospectus
S-3ASR
Automatic shelf registration
24 Nov 23
S-8
Registration of securities for employees
10 Aug 23
S-8
Registration of securities for employees
5 Aug 21
S-8
Registration of securities for employees
31 Dec 20
SC TO-T/A
Third party tender offer statement (amended)
13 Oct 20
SC TO-T/A
Third party tender offer statement (amended)
2 Oct 20
SC TO-T/A
Third party tender offer statement (amended)
30 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
29 Sep 20
SC TO-T/A
Third party tender offer statement (amended)
24 Sep 20
SC TO-T
Third party tender offer statement
14 Sep 20
Proxies
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
DEFA14A
Additional proxy soliciting materials
20 Apr 23
DEF 14A
Definitive proxy
20 Apr 23
DEFA14A
Additional proxy soliciting materials
20 Apr 22
DEF 14A
Definitive proxy
20 Apr 22
DEFA14A
Additional proxy soliciting materials
20 May 21
DEFA14A
Additional proxy soliciting materials
23 Apr 21
DEF 14A
Definitive proxy
23 Apr 21
DEFA14A
Additional proxy soliciting materials
24 Apr 20
Other
UPLOAD
Letter from SEC
26 Jan 21
CORRESP
Correspondence with SEC
14 Jan 21
UPLOAD
Letter from SEC
30 Dec 20
CT ORDER
Confidential treatment order
3 Dec 20
CORRESP
Correspondence with SEC
24 Sep 20
CT ORDER
Confidential treatment order
24 Mar 20
CT ORDER
Confidential treatment order
24 Mar 20
CT ORDER
Confidential treatment order
24 Mar 20
CT ORDER
Confidential treatment order
24 Mar 20
CT ORDER
Confidential treatment order
24 Mar 20
Ownership
4
Joseph Baroldi
17 Apr 24
4
Brian Birchler
17 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
4
Kyle Jenne
13 Mar 24
3
Kyle Jenne
13 Mar 24
4
Eric Swayze
4 Mar 24
4
Brett P Monia
4 Mar 24
4
Richard S Geary
4 Mar 24
4
Brian Birchler
4 Mar 24